14.3 Immunology: Innate & Adaptive Immunity, the Immune Response, Antibodies, Complement, Cytokines & MHC
Key Takeaways
Innate immunity (barriers, phagocytes, NK cells, complement, pattern-recognition receptors such as Toll-like receptors) is immediate and non-specific; adaptive immunity (B and T cells) is specific, slower at first and leaves memory.
MHC class I (all nucleated cells) presents intracellular peptides to CD8 cytotoxic T cells; MHC class II (antigen-presenting cells) presents extracellular peptides to CD4 helper T cells.
IgM is the first antibody made and the best complement activator; IgG is the most abundant, crosses the placenta and dominates secondary responses; IgA protects mucosae and is in breast milk; IgE mediates allergy and helminth immunity.
The classical pathway starts with antigen-antibody complexes (C1q), the lectin pathway with mannose-binding lectin, and the alternative pathway spontaneously on microbial surfaces; all converge on C3, and C5b-9 forms the membrane attack complex.
IL-1, IL-6 and TNF-alpha drive fever and the acute-phase response; IL-2 expands T cells; IFN-gamma activates macrophages (Th1); IL-4, IL-5 and IL-13 drive IgE and eosinophils (Th2); IL-10 and TGF-beta suppress.
Why this area matters
The TOS lists "innate and acquired immunity (functions of immune system, events in the immune response, humoral versus cell-mediated immunity, antigen and antibody interaction), role of cytokines, MHC class I and II". These basics explain how vaccines work, why newborns rely on maternal IgG and breast milk IgA, what serologic tests mean (dengue IgM, HBsAg, anti-HBs) and how immunodeficiencies present.
Innate and adaptive immunity
| Feature | Innate immunity | Adaptive (acquired) immunity |
|---|---|---|
| Components | Skin and mucosal barriers, lysozyme, stomach acid, neutrophils, macrophages, dendritic cells, NK cells, complement, acute-phase proteins, interferons | B lymphocytes (antibodies) and T lymphocytes (CD4 helper, CD8 cytotoxic, regulatory) |
| Recognition | Germline pattern-recognition receptors (Toll-like receptors) detecting PAMPs such as LPS, flagellin and viral nucleic acids | Highly diverse antigen receptors from V(D)J recombination |
| Speed | Minutes to hours | Days on first exposure (primary response) |
| Memory | None | Memory: faster, larger secondary response, the basis of vaccination |
NK cells kill virus-infected and tumor cells that have lost MHC class I (the "missing self" mechanism) and cells coated with IgG (antibody-dependent cellular cytotoxicity).
Events in an immune response
- Recognition and capture: dendritic cells take up antigen at the site of entry and carry it to the lymph nodes.
- Presentation: peptides are displayed on MHC molecules to naive T cells.
- Activation: this needs two signals: the T-cell receptor binding peptide-MHC (signal 1) plus co-stimulation by CD28 binding B7 (CD80/86) (signal 2). Without signal 2, the T cell becomes anergic.
- Clonal expansion and differentiation: IL-2 drives proliferation. CD4 cells differentiate into Th1, Th2, Th17 or follicular helper cells, and CD8 cells into cytotoxic cells.
- Effector phase:
- Humoral: B cells, helped by T follicular helper cells through CD40L-CD40, undergo class switching and affinity maturation in germinal centers and become plasma cells.
- Cell-mediated: cytotoxic T cells kill infected cells with perforin, granzymes and Fas ligand, and Th1 cells activate macrophages.
- Contraction and memory: most effector cells die, and memory B and T cells remain.
| Humoral immunity | Cell-mediated immunity |
|---|---|
| Antibodies from B cells and plasma cells | T cells (CD8 killing; CD4 Th1 macrophage activation) |
| Best against extracellular bacteria, toxins and free viruses | Best against intracellular pathogens (viruses, mycobacteria, fungi), tumors and grafts |
| Effector actions: neutralization, opsonization, complement activation, ADCC | Effector actions: cytotoxicity, delayed-type hypersensitivity, granulomas |
| Tests: serology | Tests: tuberculin skin test, interferon-gamma release assays |
Antibodies and antigen-antibody interactions
An antibody has two identical heavy and two identical light chains (kappa or lambda). The Fab fragment binds antigen through the variable regions, which contain the hypervariable regions or CDRs. The Fc fragment determines class functions: complement binding and Fc receptor binding.
| Class | Key features |
|---|---|
| IgG | Most abundant in serum; crosses the placenta and protects newborns for about 6 months; main antibody of the secondary response; opsonizes and activates complement; subclasses IgG1 to IgG4 |
| IgM | First antibody in a primary response; a pentamer (10 binding sites), so the best complement activator; B-cell receptor (monomer); a positive IgM suggests recent infection (dengue IgM, anti-HAV IgM, anti-HBc IgM) |
| IgA | Mucosal antibody; secretory IgA is a dimer with J chain and secretory component; in breast milk and colostrum; does not fix complement well |
| IgE | Binds mast cells and basophils; allergy (type I hypersensitivity) and helminth defense |
| IgD | On naive B cells with IgM; function poorly defined |
Antigen-antibody reactions are non-covalent: hydrogen bonds, electrostatic, van der Waals and hydrophobic forces. Their strength is affinity for a single site and avidity overall. Laboratory uses include:
- agglutination (blood typing, Widal test);
- precipitation;
- ELISA;
- immunofluorescence;
- lateral-flow rapid tests;
- the Coombs test for antibody-coated red cells.
The complement system
| Pathway | Trigger | Early components |
|---|---|---|
| Classical | Antigen-antibody complexes (IgM, IgG) | C1q, C1r, C1s, C4, C2 |
| Lectin | Mannose-binding lectin on microbial sugars | MASPs, C4, C2 |
| Alternative | Spontaneous C3 hydrolysis on microbial surfaces | C3, factor B, factor D, properdin |
All three converge on C3 convertase. C3b is an opsonin. C3a and C5a are anaphylatoxins, and C5a is also a neutrophil chemoattractant. C5b-9 forms the membrane attack complex.
Regulators: C1 esterase inhibitor (its deficiency causes hereditary angioedema), and decay-accelerating factor and CD59 (their loss causes paroxysmal nocturnal hemoglobinuria).
Deficiencies: early classical components (C1, C2, C4) predispose to SLE; C3 deficiency to severe pyogenic infections; and C5 to C9 deficiency to recurrent Neisseria infections.
Cytokines
| Cytokine | Main source | Main actions |
|---|---|---|
| IL-1, TNF-alpha, IL-6 | Macrophages | Fever, acute-phase response (IL-6 drives CRP and hepcidin), endothelial activation; TNF causes cachexia and septic shock |
| IL-8 (CXCL8) | Macrophages, endothelium | Neutrophil chemotaxis |
| IL-12 | Macrophages, dendritic cells | Drives Th1 differentiation |
| IL-2 | T cells | T-cell proliferation (blocked by calcineurin inhibitors such as cyclosporine) |
| IFN-gamma | Th1 cells, NK cells | Activates macrophages (granulomas); increases MHC expression |
| IL-4, IL-5, IL-13 | Th2 cells | IgE class switching (IL-4), eosinophils (IL-5), mucus |
| IL-17 | Th17 cells | Neutrophil recruitment (psoriasis, autoimmunity) |
| IL-10, TGF-beta | Regulatory T cells, M2 macrophages | Suppress inflammation; TGF-beta drives fibrosis and IgA class switching |
| Type I interferons (alpha, beta) | Virus-infected cells | Antiviral state; activate NK cells |
MHC (HLA) molecules
| Feature | MHC class I (HLA-A, -B, -C) | MHC class II (HLA-DR, -DP, -DQ) |
|---|---|---|
| Found on | All nucleated cells (not red cells) | Antigen-presenting cells: dendritic cells, macrophages, B cells |
| Peptide source | Endogenous (cytosolic): viral and tumor proteins, processed by the proteasome and moved by TAP into the ER | Exogenous: endocytosed proteins in endosomes; invariant chain blocks the groove until loading |
| T-cell partner | CD8 cytotoxic T cells | CD4 helper T cells |
| Structure | Alpha chain plus beta-2-microglobulin | Alpha and beta chains |
MHC genes on chromosome 6 are highly polymorphic, which matters for transplant matching. Some disease associations are HLA-B27 (ankylosing spondylitis), HLA-DR3 and DR4 (type 1 diabetes) and HLA-DQ2 and DQ8 (celiac disease).
Immunity and vaccines
- Active immunity comes from infection or vaccination. It is slow to develop but long-lasting, with memory.
- Passive immunity comes from maternal IgG, breast-milk IgA, or immune globulins (rabies, tetanus and hepatitis B immune globulin, antivenom). It is immediate but temporary.
- Live attenuated vaccines (MMR, BCG, oral polio, varicella) induce strong cellular immunity but are generally avoided in pregnancy and severe immunodeficiency.
- Inactivated, subunit, toxoid and conjugate vaccines need boosters.
- Conjugating a polysaccharide to a protein carrier (Hib, pneumococcal conjugate) converts a T-independent response into a T-dependent one that works in infants under 2 years.
A virus-infected hepatocyte displays viral peptides that are recognized by cytotoxic T lymphocytes. Through which molecule and pathway are these peptides presented?
CD1, after lipid processing in lysosomes
MHC class I, after proteasomal processing and TAP transport into the ER
MHC class II, after endosomal processing with the invariant chain and HLA-DM loading
Free in the cytosol, without any MHC molecule
A 5-day-old baby has antibodies against measles in his blood, although he has never been infected or vaccinated. Which antibody class explains this, and what kind of immunity is it?
Maternal IgG that crossed the placenta, giving passive immunity
Maternal IgA absorbed from colostrum into the blood, giving active immunity
Fetal IgM made in response to maternal antigens, giving active immunity
Fetal IgE produced after birth, giving passive immunity
A boy has had two episodes of meningococcal meningitis. Deficiency of which complement components is most likely?
The terminal components C5 to C9 that form the membrane attack complex
Decay-accelerating factor (CD55)
C1 esterase inhibitor
Early classical pathway components C1, C2 and C4 that start the cascade and activate C3
Sections you finish are checked off in the contents.